All In Biotech

NDA 020629 · Mylan

Denavir

Penciclovir · Topical · Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor

Novel

Last checked: Nov 20, 2026Latest source record: Nov 21, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Sep 24, 1996

Approved uses

2

Original approval plus efficacy supplements

Registered trials

4

1 Phase 3, 0 recruiting

FAERS reports

362

217 serious, 24 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 4, 2019.

Penciclovir cream is a deoxynucleoside analog HSV DNA polymerase inhibitor indicated for the treatment of recurrent herpes labialis (cold sores) in adults and children 12 years of age or older. Penciclovir cream is a deoxynucleoside analog HSV DNA polymerase inhibitor indicated for the treatment of recurrent herpes labialis (cold sores) in adults and pediatric patients 12 years of age and older. ( 1 )

Mechanism: Penciclovir is an antiviral agent active against alpha herpes viruses [see Microbiology (12.4) ]. Mechanism of Action Penciclovir has inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2). In cells infected with HSV-1 or HSV-2, the viral thymidine kinase phosphorylates penciclovir to a monophosphate form that, in turn, is converted by cellular kinases to the active form penciclovir triphosphate. Biochemical studies demonstrate that penciclovir triphosphate inhibits HSV DNA polymerase competitively with deoxyguanosine triphosphate. Consequently, α-herpes viral DNA...

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 10, 2003 Supplement 8 · Efficacy LabelLetter
  • Sep 24, 1996 Original approval · Type 1 - New Molecular Entity Review
1 products under this application
  • DENAVIR · PENCICLOVIR 1% · CREAM, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Penciclovir" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective46
  • headache31
  • fatigue28
  • pain26
  • diarrhoea25
  • hypertension22
  • chronic kidney disease20
  • cough20
  • vomiting20
  • anaemia18
  • condition aggravated18
  • nausea18

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
20056
200611
200710
20086
20099
201010
201114
201210
201313
20148
201527
201649
201728
201831
201932
202020
202116
202218
20239
20248
20258
202611

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Denavir (Penciclovir)

2024 spending

$466K

Beneficiaries

257

518 claims

Per beneficiary

$1,812

$155.22 per unit

View as table
YearSpending
2020$6,527,909
2021$5,566,596
2022$4,882,912
2023$889,206
2024$465,663

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 39 on PubMed

Sponsor: Mylan

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.